Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VCAR 33

Next Previous
X
Search
Drug Profile

VCAR 33

Alternative Names: Anti-CD33 chimeric antigen receptor T-cell therapy - Vor Biopharma; VCAR-33; VCAR33ALLO; VCAR33AUTO

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Vor Biopharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 20 Mar 2024 VCAR 33 receives Fast Track designation for Acute myeloid leukaemia [Parenteral] (In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater, In adults) in USA
  • 20 Mar 2024 VCAR 33 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 02 Nov 2023 Adverse events data from a phase I/II trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting (ASH-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top